Get more information on Immunology Market - Request Free Sample Report
The Immunology Market Size was valued at USD 97.58 Billion in 2023, and is expected to reach USD 254.23 Billion by 2032, and grow at a CAGR of 11.8%.
Exposure to toxic chemicals, stress, dietary components, gut dysbiosis, and infections among various other environmental factors lead to a substantial number of patients affected by autoimmune diseases. Currently, autoimmune diseases are the third leading chronic illness in the U.S., and approximately 50 million people in the country have at least one form of autoimmune disease. For example, UK data, published by the University of Oxford in May 2023, population-based study that included 22.0 million individuals indicates that one in ten people is suffering from the autoimmune disorders.
Moreover, the demand for these medications among the patient population are encouraging market players to develop and launch their new medication in the global immunology market. The market growth is also encouraged by the rising regulatory approvals of new medications for the treatment of autoimmune diseases. For example, as of February 2023, Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration approved KEVZARA to treat polymyalgia rheumatica, an inflammatory rheumatic disease. The growth of the market is expected to be accelerated over the forecast period, owing to the increasing awareness of autoimmune diseases in developed and developing countries, as well as on the potential pipeline candidates.
Key Drivers:
The Rising Prevalence of Autoimmune Diseases, Such as Rheumatoid Arthritis, Multiple Sclerosis, and Type 1 Diabetes, is A Significant Driver of the Immunology Market.
The Development and Approval of Biologics and Targeted Therapies have Revolutionized the Treatment of Immunological Disorders.
Restraints:
One of the Primary Challenges in the Immunology Market is the High Cost Associated with Biologic Therapies and Advanced Immunological Treatments.
The Immunology Market is Heavily Regulated, with Stringent Requirements for The Approval of New Drugs and Therapies.
Opportunity:
Immunotherapy Is Gaining Traction as a Promising Approach in Oncology, offering Opportunities for Market Expansion Beyond Traditional Immunological Disorders.
The Increasing Emphasis on Precision Medicine Presents a Significant Opportunity in the Immunology Market.
By Drug Class
The monoclonal antibody segment held the largest share of 58% in 2023. The increasing efficacy associated with monoclonal antibodies for treating chronic and rare diseases including autoimmune diseases is contributing to segment growth. The antibodies include, infliximab, rituximab, adalimumab among others. Moreover, a higher number of approvals for mAbs for treating different diseases is further supporting segment growth. For example, In January 2023, Gilead Sciences, Inc. entered into a collaboration with EVOQ Therapeutics, Inc., to leverage EVOQ’s NanoDisc technology for developing a treatment for Rheumatoid Arthritis and lupus.
Get Customized Report as per your Business Requirement - Request For Customized Report
The immunosuppressants segment is expected to grow at the highest CAGR during the forecast period. The rapid growth of the segment is attributed to a strong focus on R&D by prime market players to establish a higher number of regulatory approvals. Moreover, higher efficacy of immunosuppressants is contributing to the fast growth resulting in an over rush in their utilization in developing markets thereby propelling a higher CAGR.
By Indication
The rheumatoid arthritis segment held a dominant share that was 43% by 2023. An increasing number of patients seeking treatment and the growing prevalence of rheumatoid arthritis will result in a growing demand for drugs from the rheumatoid arthritis segment. For instance, according to the Australian Bureau of Statistics that published the statistics in 2023, in Australia, there were an estimated 3.7 million people with arthritis, and about 13.9% are suffering from rheumatoid arthritis.
On the other hand, limited drug approvals for conditions such as ankylosing spondylitis, inflammatory bowel disease, and others, and the high cost of currently marketed drugs, are hindering their adoption by the patient population, especially in the emerging countries.
North America, and more specifically the U.S., continues to dominate immunology market share with 32% share in 2023 as it provides significant healthcare expenditure, excellent R&D infrastructure, and the high uptake of advanced therapeutics. Europe is next with significant investment in biotechnology and innovative immunology therapies, primarily in Germany, France, and the U.K.
Asia-Pacific is growing the fastest due to the number of patients, expansion in healthcare expenditure in countries such as China and India, and improved resources making advanced therapies more readily available. In 2022, the Victorian Government in Australia has provided a $100,000 grant to the Hudson Institute of Medical Research to explore affordable and more accessible RNA-based treatments for autoimmune diseases. This clearly showcases the advances in RNA predictive sciences and immunology and, overall, the ability of RNA therapeutics to revolutionize the medication of autoimmune conditions.
In February 2022, NIH provided a webinar on the purpose of autoimmune diseases and women’s health. Mostly affecting women, with 8 out of 10 people with a chronic autoimmune condition in the U.S. being female, the phenomenon was presented during the event. Finally, the World Health Organization is looking to better extend the access to care for RA in a number of ways, with two of the examples including the aim of Rehabilitation 2030 and the UN Decade of Healthy Ageing to promote healthy ageing and improve the satisfaction of older people with RA in all their specific and diverse needs.
The key market players are Novartis AG, AbbVie, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., F. Hoffmann-La Roche Ltd., Astellas Pharma Inc., Pfizer Inc., Janssen Global Services, LLC, Merck Sharp, Dohme Corp. & other players.
In June 2023- Sandoz launched Hyrimoz injection, a high-concentration formulated used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and other immunological diseases
In March 2023 – Eli Lilly and Company received approval from the Indian regulatory agency Directorate General of Commercial Intelligence and Statistics allowing it to launch its drug, Copellor, for the treatment of moderate-to-severe plaque psoriasis as well as treatment of psoriatic arthritis.
In June 2022 – Eli Lilly and Company U.S. Food and Drug Administration approved OLUMIANT as a first-in-disease systemic treatment for adults suffering from severe alopecia areata (Auto-immune disorder).
| Report Attributes | Details |
| Market Size in 2023 | US$ 97.58 Billion |
| Market Size by 2032 | US$ 254.23 Billion |
| CAGR | CAGR of 11.8% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | •By Drug Class (Monoclonal Antibody (mAb), Fusion Proteins, Immunosuppressants, and Others) •By Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, and Others) •By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Novartis AG, AbbVie, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., F. Hoffmann-La Roche Ltd., Astellas Pharma Inc., Pfizer Inc., Janssen Global Services, LLC, Merck Sharp, Dohme Corp. & other players |
| Key Drivers | •The Rising Prevalence of Autoimmune Diseases, Such as Rheumatoid Arthritis, Multiple Sclerosis, and Type 1 Diabetes, is A Significant Driver of the Immunology Market. •The Development and Approval of Biologics and Targeted Therapies have Revolutionized the Treatment of Immunological Disorders. |
| RESTRAINTS | •One of the Primary Challenges in the Immunology Market is the High Cost Associated with Biologic Therapies and Advanced Immunological Treatments. •The Immunology Market is Heavily Regulated, with Stringent Requirements for The Approval of New Drugs and Therapies. |
The Compound Annual Growth rate for the immunology market over the forecast period is 11.8%.
The projected market size for the immunology market is USD 254.23 billion in 2032.
The high cost of treatments and their unfavorable side effects.
Immunology market growth is anticipated by growing novel therapies and rising prevalence of autoimmune disorders.
North America dominated the global market in 2023
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.5 Innovation and R&D, by Drug Class, 2023
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Drug Volume: Production and usage volumes of pharmaceuticals.
5.4 Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients.
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and supply chain strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Immunology Market Segmentation, by Drug Class
7.1 Chapter Overview
7.2 Monoclonal Antibody
7.2.1 Monoclonal Antibody Market Trends Analysis (2020-2032)
7.2.2 Monoclonal Antibody Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Immunosuppressants
7.3.1 Immunosuppressants Market Trends Analysis (2020-2032)
7.3.2 Immunosuppressants Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Fusion Proteins
7.4.1 Fusion Proteins Market Trends Analysis (2020-2032)
7.4.2 Fusion Proteins Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Others
7.5.1 Others Market Trends Analysis (2020-2032)
7.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Immunology Market Segmentation, by Indication
8.1 Chapter Overview
8.2 Rheumatoid Arthritis
8.2.1 Rheumatoid Arthritis Market Trends Analysis (2020-2032)
8.2.2 Rheumatoid Arthritis Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Psoriatic Arthritis
8.3.1 Psoriatic Arthritis Market Trends Analysis (2020-2032)
8.3.2 Psoriatic Arthritis Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Plaque Psoriasis
8.4.1 Plaque Psoriasis Market Trends Analysis (2020-2032)
8.4.2 Plaque Psoriasis Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Ankylosing Spondylitis
8.5.1 Ankylosing Spondylitis Market Trends Analysis (2020-2032)
8.5.2 Ankylosing Spondylitis Market Size Estimates and Forecasts to 2032 (USD Billion)
8.6 Inflammatory Bowel Disease
8.6.1 Inflammatory Bowel Disease Market Trends Analysis (2020-2032)
8.6.2 Inflammatory Bowel Disease Market Size Estimates and Forecasts to 2032 (USD Billion)
8.7 Prophylaxis of Organ Rejection
8.7.1 Prophylaxis of Organ Rejection Market Trends Analysis (2020-2032)
8.7.2 Prophylaxis of Organ Rejection Market Size Estimates and Forecasts to 2032 (USD Billion)
8.8 Others
8.8.1 Others Market Trends Analysis (2020-2032)
8.8.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Immunology Market Segmentation, by Distribution Channel
9.1 Chapter Overview
9.2 Hospital Pharmacies
9.2.1 Hospital Pharmacies Market Trends Analysis (2020-2032)
9.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Retail Pharmacies
9.3.1 Retail Pharmacies Market Trends Analysis (2020-2032)
9.3.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Online Pharmacies
9.4.1 Online Pharmacies Market Trends Analysis (2020-2032)
9.4.2 Online Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Immunology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.2.4 North America Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.2.5 North America Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.2.6.2 USA Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.2.6.3 USA Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.2.7.2 Canada Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.2.7.3 Canada Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.2.8.2 Mexico Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.2.8.3 Mexico Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Immunology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.6.2 Poland Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.1.6.3 Poland Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.7.2 Romania Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.1.7.3 Romania Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.9 Turkey
10.3.1.9.1 Turkey Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Immunology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.4 Western Europe Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.5 Western Europe Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.6.2 Germany Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.6.3 Germany Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.7.2 France Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.7.3 France Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.8.2 UK Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.8.3 UK Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.9.2 Italy Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.9.3 Italy Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.10.2 Spain Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.10.3 Spain Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.13.2 Austria Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.13.3 Austria Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Immunology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.4 Asia Pacific Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.5 Asia Pacific Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.6.2 China Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.6.3 China Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.7.2 India Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.7.3 India Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.8.2 Japan Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.8.3 Japan Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.9.2 South Korea Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.9.3 South Korea Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.10.2 Vietnam Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.10.3 Vietnam Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.11.2 Singapore Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.11.3 Singapore Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.12.2 Australia Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.12.3 Australia Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Immunology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.4 Middle East Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.1.5 Middle East Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.6.2 UAE Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.1.6.3 UAE Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Immunology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.2.4 Africa Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.2.5 Africa Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Immunology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.4 Latin America Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.6.5 Latin America Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.6.2 Brazil Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.6.6.3 Brazil Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.7.2 Argentina Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.6.7.3 Argentina Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.8.2 Colombia Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.6.8.3 Colombia Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Immunology Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Immunology Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Immunology Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
11. Company Profiles
11.1 Novartis AG
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 AbbVie, Inc.
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 Bristol-Myers Squibb Company
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Eli Lilly and Company
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Amgen Inc.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 F. Hoffmann-La Roche Ltd.
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Astellas Pharma Inc.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 Pfizer Inc.
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 Janssen Global Services, LLC
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 Merck Sharp & Dohme Corp.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Drug Class
Monoclonal Antibody
Immunosuppressants
Fusion Proteins
Others
By Indication
Rheumatoid Arthritis
Psoriatic Arthritis
Plaque Psoriasis
Ankylosing Spondylitis
Inflammatory Bowel Disease
Prophylaxis of Organ Rejection
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Neurovascular Devices Market Size was valued at USD 3.01 billion in 2023, and is expected to reach USD 4.81 billion by 2030, and grow at a CAGR of 6.05% over the forecast period 2024-2031.
The Medical Second Opinion Market Size was valued at USD 6292.6 Million in 2023, expected to reach USD 22661.78 Million by 2032, with 8.36% CAGR.
The Medical Electrodes Market size was valued at USD 1.91 Billion in 2023 & is estimated to reach USD 2.84 Billion by 2032 with a growing CAGR of 4.50% between 2024 and 2032.
The Personalized Medicine Market was valued at USD 530.01 billion in 2023, and is expected to reach USD 1,078.17 billion by 2032, and grow at a CAGR of 8.21% over the forecast period 2024-2032.
The Medical Nonwoven Disposable Market Size was valued at USD 25.0 billion in 2023 and is expected to reach USD 67.99 billion by 2031 and grow at a CAGR of 13.3% over the forecast period 2024-2031.
The global Upstream Bioprocessing market, valued at USD 24.20 Billion in 2023, is projected to reach USD 81.15 Billion by 2032, growing at a compound annual growth rate CAGR of 15.22% during the forecast period.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
